Zentalis shakes up PhIII plans in ovarian cancer; Halozyme’s deal with Acumen; Korro’s $117M private placement

Zentalis Pharma shakes up plans for Phase III in ovarian cancer: Zentalis announced Monday that it is no longer planning to test its lead candidate, azenosertib, in combination with chemotherapy in second-line platinum-sensitive ovarian cancer (PSOC) patients. The Phase III study was expected to start in…
Click here to view original post